Project description: More than 400,000 patients in the US have end stage renal disease (ESRD), a population expected to double in the next decade. The long term goal of this current proposal and research program is to improve the care of patients with ESRD, the vast majority of who use long-term hemodialysis as their mode of renal replacement therapy. These patients require highly functioning vascular access for optimal therapeutic adequacy. Hemodialysis vascular access failure is frequently from venous stenosis secondary to neointimal hyperplasia (VNH). Preliminary data from our studies indicate that several mechanisms may be responsible for VNH formation. These include: 1) Elevated hypoxia inducible factor-1 alpha (HIF-11) which then stimulates;2) Increased expression of vascular endothelial growth factor-A (VEGF-A) and its receptors;3) Increased expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 (gelatinases);and 4) Proliferation and migration of fibroblasts from the adventitia and media to the intima resulting in VNH formation. We have developed state- of-the art molecular reagents and validated mouse nephrectomy with arteriovenous fistula model (AVF) and a hypoxia fibroblast cell culture model. The in vitro and in vivo models and accompanying reagents allow us to rigorously test our Central Hypothesis: Venous neointimal hyperplasia occurs when increased HIF-11 stimulates adventitial fibroblasts to differentiate into myofibroblasts (1-SMA positive cells). Increased expression of HIF-11 regulated proteins including VEGF-A, MMP-2 and MMP-9 results in the proliferation and migration of myofibroblasts into the intima leading to the formation of VNH. To test our central hypothesis we have developed three specific aims: 1). Determine the temporal and spatial role(s) of VEGF-A in VNH. 2). Determine the role(s) and regulation of MMPs in VNH. 3). Determine if the molecular mechanism of hypoxia induced fibroblast to myofibroblast differentiation is mediated by the VEGF- A/MMP axes. Successful completion of these aims will allow us to ultimately translate therapies aimed at inhibiting VNH to clinical trials thereby improving patient outcomes using commercially available anti-VEGF-A antibodies (Avastin (Bevacizumab)) and MMP inhibitors (Simvastatin or Sirolimus) which can be delivered using catheter based technology.

Public Health Relevance

Public Health Relevance Statement: More than 400,000 patients in the US have end stage renal disease (ESRD), a population expected to double in the next decade. The long term goal of this current proposal and research program is to improve the care of patients with ESRD, the vast majority of who use long-term hemodialysis as their mode of renal replacement therapy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL098967-03
Application #
8214595
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Reid, Diane M
Project Start
2010-02-01
Project End
2015-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
3
Fiscal Year
2012
Total Cost
$557,660
Indirect Cost
$188,593
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Khangura, Kirandeep K; Eirin, Alfonso; Kane, Garvan C et al. (2014) Cardiac function in renovascular hypertensive patients with and without renal dysfunction. Am J Hypertens 27:445-53
Mendes, Bernardo C; Oderich, Gustavo S; Fleming, Mark D et al. (2014) Clinical significance of embolic events in patients undergoing endovascular femoropopliteal interventions with or without embolic protection devices. J Vasc Surg 59:359-367.e1
Brahmbhatt, Akshaar; NievesTorres, Evelyn; Yang, Binxia et al. (2014) The role of Iex-1 in the pathogenesis of venous neointimal hyperplasia associated with hemodialysis arteriovenous fistula. PLoS One 9:e102542
Yang, Binxia; Janardhanan, Rajiv; Vohra, Pawan et al. (2014) Adventitial transduction of lentivirus-shRNA-VEGF-A in arteriovenous fistula reduces venous stenosis formation. Kidney Int 85:289-306
Nieves Torres, Evelyn C; Yang, Binxia; Roy, Bhaskar et al. (2014) Adventitial delivery of lentivirus-shRNA-ADAMTS-1 reduces venous stenosis formation in arteriovenous fistula. PLoS One 9:e94510
Janardhanan, Rajiv; Misra, Sanjay (2014) The authors reply. Kidney Int 86:446
Ketha, Siva S; Bjarnason, Haraldur; Oderich, Gustavo S et al. (2014) Clinical features and endovascular management of iliac artery fibromuscular dysplasia. J Vasc Interv Radiol 25:949-53
McKenzie, Gavin A; Oderich, Gustavo S; Kawashima, Akira et al. (2013) Renal artery fibromuscular dysplasia in 2,640 renal donor subjects: a CT angiography analysis. J Vasc Interv Radiol 24:1477-80
McDonald, Robert J; McDonald, Jennifer S; Bida, John P et al. (2013) Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 267:106-18
Misra, Sanjay; Lookstein, Robert; Rundback, John et al. (2013) Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia. J Vasc Interv Radiol 24:451-8

Showing the most recent 10 out of 20 publications